
U.S. equities advanced on Friday, with the Dow, NASDAQ, and S&P 500 all gaining, even as the Federal Reserve's preferred inflation gauge, the Personal Consumption Expenditures (PCE) price index, showed no signs of cooling. August PCE inflation rose 2.7% year-over-year, up from 2.6% in July and marking its highest reading since February 2025, alongside robust personal spending and income growth. This persistent inflationary pressure is reigniting questions regarding the market's aggressive expectations for future Federal Reserve rate cuts.
U.S. equity markets demonstrated resilience, with the Dow Jones, S&P 500, and NASDAQ gaining 0.58%, 0.47%, and 0.31% respectively, despite troubling inflation signals. The core concern stems from the Federal Reserve's preferred inflation metric, the Personal Consumption Expenditures (PCE) price index, which accelerated to 2.7% year-over-year in August from 2.6% in July, with the monthly rate also ticking up to 0.3%. This persistent inflation, described as the highest since February 2025 in the report, challenges the market's expectations for aggressive rate cuts, especially when coupled with stronger-than-expected personal spending (+0.6%) and income (+0.4%) data. Sector performance showed a risk-on tilt with Energy shares rising 1% while defensive Consumer Staples fell 0.3%. At the single-stock level, there was extreme divergence driven by idiosyncratic events: MEDIROM Healthcare (MRM) and bioAffinity Technologies (BIAF) surged 155% and 92% on company-specific operational and clinical news, whereas Pop Culture Group (CPOP) and Lexaria Bioscience (LEXX) plummeted 52% and 27% following announcements of dilutive share offerings.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mixed
Sentiment Score
0.00
Ticker Sentiment